Application of Glutamine-enriched nutrition therapy in childhood acute lymphoblastic leukemia
- PMID: 27401338
- PMCID: PMC4940940
- DOI: 10.1186/s12937-016-0187-4
Application of Glutamine-enriched nutrition therapy in childhood acute lymphoblastic leukemia
Abstract
Background: We investigated the effects of glutamine (Gln)-enriched nutritional therapy during chemotherapy on the nutritional status and immune function of children with acute lymphoblastic leukemia (ALL).
Methods: We enrolled 48 children who were newly diagnosed with ALL in our department during the period of 2013.1-2014.12. The patients (follow random number table) were randomly divided into the control group (peptamen) and the treatment group (peptamen + glutamine), 24 cases in each group. The remission induction regimens were all based on VDLP (D) chemotherapy (VCR (Vincrisstine), DNR (Daunomycin), L-ASP (L-Asparagiase), Prednisolone and Dexamethasone). The treatment group received Gln-enriched nutritional therapy every day during the full course of chemotherapy,and the control group is as same as the treatment group except without glutamine. The indicators of general nutritional status, such as weight, height, and triceps skinfold thickness, and the indicators of biochemical tests, such as serum albumin, prealbumin, creatinine-height index, retinol binding protein, and urinary hydroxyproline index, were compared between the two groups at the end of the first, second, third and the fourth week when the chemotherapy was completed. And in the fourth week, flow cytometry was applied to detect the levels of T cell subsets and the activities of natural killer (NK) cells in peripheral blood of the two groups.
Results: 1. after 4 weeks nutritional therapy, there is no significant difference (p > 0.05) between the two groups of children in weight, height and other indicators. 2. At the end of 2 weeks treatment, the level of prealbumin (PA) and retinol-binding protein (RBP) is higher in treatment group than that in the control group (P <0.05), at the end of 3 weeks treatment, the thickness of triceps skinfold is higher (P <0.05) than that in the control group; 3. At the end of 3 and 4 weeks, the concentrations serum ALB, PA, RBP and UHI were higher than in the control group (P <0.05); 4. There is statistically significant (p < 0.05) between the two groups in edema incidence; 5. At the end of treatment (4 weeks), the percentages of CD3 +, CD4 +, CD4 +/CD8 +, NK cell are significantly decreased in the two groups (P <0.05).
Conclusion: Gln-enriched nutritional therapy can effectively improve the systemic nutritional status of children with leukemia, improve immune function.
Keywords: Childhood acute lymphoblastic leukemia (ALL); Creatinine-height index (CHI); Glutamine (Gln); Immune function; Nutrition therapy; Prealbumin (PA); Retinol binding protein (RBP); Serum albumin (ALB); Urinary hydroxyproline index (UHI).
Similar articles
-
Clinical analysis of immune reconstitution after chemotherapy in children with acute lymphoblastic leukemia.BMC Pediatr. 2024 Aug 30;24(1):557. doi: 10.1186/s12887-024-05030-4. BMC Pediatr. 2024. PMID: 39215273 Free PMC article.
-
Nutritional status of children with leukemia.Med Pediatr Oncol. 1994;22(2):73-7. doi: 10.1002/mpo.2950220202. Med Pediatr Oncol. 1994. PMID: 8259104
-
Clinical application of immune-enhanced enteral nutrition in patients with advanced gastric cancer after total gastrectomy.J Dig Dis. 2012 Aug;13(8):401-6. doi: 10.1111/j.1751-2980.2012.00596.x. J Dig Dis. 2012. PMID: 22788925 Clinical Trial.
-
Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. doi: 10.1097/00043426-200112000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11902303 Review.
-
The evolution of nutritional care in children and young people with acute lymphoblastic leukaemia: a narrative review.J Hum Nutr Diet. 2025 Feb;38(1):e13273. doi: 10.1111/jhn.13273. Epub 2024 Jan 7. J Hum Nutr Diet. 2025. PMID: 38185902 Free PMC article. Review.
Cited by
-
What makes a good new therapeutic L-asparaginase?World J Microbiol Biotechnol. 2019 Sep 24;35(10):152. doi: 10.1007/s11274-019-2731-9. World J Microbiol Biotechnol. 2019. PMID: 31552479 Review.
-
Diet as a Potential Moderator for Genome Stability and Immune Response in Pediatric Leukemia.Cancers (Basel). 2021 Jan 22;13(3):413. doi: 10.3390/cancers13030413. Cancers (Basel). 2021. PMID: 33499176 Free PMC article. Review.
-
Glutamine and leukemia research: progress and clinical prospects.Discov Oncol. 2024 Aug 31;15(1):391. doi: 10.1007/s12672-024-01245-0. Discov Oncol. 2024. PMID: 39215845 Free PMC article. Review.
-
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.J Transl Med. 2024 Mar 13;22(1):274. doi: 10.1186/s12967-024-04990-6. J Transl Med. 2024. PMID: 38475814 Free PMC article.
-
Intervention and Mechanisms of Alanyl-glutamine for Inflammation, Nutrition, and Enteropathy: A Randomized Controlled Trial.J Pediatr Gastroenterol Nutr. 2020 Sep;71(3):393-400. doi: 10.1097/MPG.0000000000002834. J Pediatr Gastroenterol Nutr. 2020. PMID: 32826717 Free PMC article. Clinical Trial.
References
-
- Brandalise SR, Pinheiro VR, Aguiar SS, Matsuda EI, Otubo R, et al. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group-Protocol ALL-99. J Clin Oncol. 2010;28:1911. doi: 10.1200/JCO.2009.25.6115. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous